Aim: The primary goal of this research is to judge against and the safety and effective action of CIDMUS and Dapagliflozin in individuals with heart failure. To observe the prosperity and sufficiency of Dapagliflozin in contrast to CIDMUS. To analyze the expense adequacy of both the medications. To see how much percentage of EF improved after taking Dapagliflozin. Observe improvement in quality of life after administration of Dapagliflozin. Background: The majority of individuals suffer from heart failure. Dapagliflozin, an anti-diabetic medication that belongs to the Sodium Glucose co-transporter 2 inhibitor family, is currently being used to treat heart failure. The goal of this research is to assess the drug's safety and viability. Methodology: This is a prospective, observational based study done in Aster prime hospital for 6 months in cardiology department. A minimum of 115 cases of heart failure patients were collected. This data was noted in the data collection sheets. Data includes the age, gender, and diagnosis, lab reports (which include HbA1c levels, ejection fraction, pro-BNP and KCCQ-12 score). SAS version 9.4 was used to examine and analyse all of the aforementioned factors. Results: In our study 115 HF patients were first collected and then analyzed with diverse statistical and analytical methods using SAS version 9.4 which includes mean, standard deviation, chi-square test and dependent T-test. Our study showed that 50-59 (35.38%) and 60-69 (32.30%) are more affected with co-morbidities. Whereas safety and efficacy of dapagliflozin compared with CIDMUS was similar (P <0.00001) and 2D ECHO parameters had been improved in similar after both the treatments. CIDMUS was about twice more in price than Dapagliflozin (calculated using cost-effective analysis). Quality of life is similar in both who were used to treat HF patients with Dapagliflozin and CIDMUS. Conclusion: The study reveals that after therapy with Dapagliflozin and CIDMUS in patients with HF and diabetes, dapagliflozin was found to show better safety, efficacy, quality of life, a fair bit of down sizing in hospitalization, mortality, and is also better in an economical aspect when compared with CIDMUS. Key Words: Heart Failure, dapagliflozin, CIDMUS, cost-effectiveness, efficacy and safety.